Alopecia Areata — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment.
Mesinkovska Natasha et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42138161/
- 2.
Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition.
Nkala Mandisi Brendon et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42089250/
- 3.
Efficacy of polyphenolic compounds for hair regeneration: a systematic review and meta-analysis of randomized controlled trials.
El Ammari Chaimae et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42057730/
- 4.
Assessment of vitamin D levels in patients with alopecia areata: a case-control study in a Tertiary Care Hospital in North India.
Garg Shivam et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42035405/
- 5.
Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study.
Zhan Jinshan et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41918293/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Recruiting — Phase 1 — Forte Biosciences, Inc.
https://clinicaltrials.gov/study/NCT07205159
- 2.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT05723198
- 3.
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Recruiting — Phase 3 — AbbVie
https://clinicaltrials.gov/study/NCT06012240
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Alopecia Areata
Alopecia areata is an autoimmune condition that causes unpredictable hair loss, ranging from small patches to complete loss of scalp or body hair. It can affect people of any age. Recent years have seen significant research advances, including new JAK inhibitor treatments now approved in several countries.
Most Recent Research
BACKGROUND: Janus kinase inhibitors (JAKis) can improve hair regrowth in alopecia areata (AA). OBJECTIVE: This study examined which treatment attributes patients value most when evaluating hypothetical JAKi-based therapies. METHODS: A discrete choice experiment was conducted among adults with ≥50% hair loss, recruited through the National Alopecia Areata Foundation (February-March 2024). Participants completed 10 binary choices comparing three hypothetical JAKi attributes: proportion with scalp hair regrowth, time to initial hair regrowth, and dosing frequency; safety attributes were held constant across profiles because the safety profiles were similar among JAKis approved for AA. Relative importance (RI) was calculated using preference weights. Additionally, participants ranked three blinded treatment profiles developed from phase 2b-3 data: drug profile A (baricitinib 4 mg), drug profile B (ritlecitinib 50 mg), and drug profile C (deuruxolitinib 8 mg). RESULTS: Among 302 patients (85% women, 81% White, mean age 43.2 years), the most valued attribute was scalp regrowth (RI = 60.0%), followed by time to initial regrowth (28.2%) and dosing frequency (11.7%). Drug profile C was most preferred (83%), and drug profile B was least preferred (85%). CONCLUSION: When considering efficacy only, patients prioritize higher efficacy and faster time to hair regrowth above dosing convenience in JAKi treatment preferences for AA.
Common Questions
What is Alopecia Areata?
Alopecia areata is an autoimmune condition that causes unpredictable hair loss, ranging from small patches to complete loss of scalp or body hair. It can affect people of any age. Recent years have seen significant research advances, including new JAK inhibitor treatments now approved in several countries.
How many clinical trials are available for Alopecia Areata?
RareWays currently indexes 149 clinical trials for Alopecia Areata, of which 35 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Alopecia Areata come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Alopecia Areata.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.